Blood test study aims to unlock secrets of Hard-to-Treat breast cancer
NCT ID NCT06706557
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is looking at genetic material from tumors (circulating tumor DNA) found in the blood of 30 people with advanced or metastatic HER2-low breast cancer. The goal is to identify specific mutations in these cancers. This is an observational study, meaning no new treatment is being tested, but the findings could help guide future research and treatment choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify genetic markers that guide treatment decisions for HER2-low breast cancer.
- What could go wrong
- This is a very small pilot study (30 participants) focused on observation, not treatment. It may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
European Institute of Oncology
RECRUITINGMilan, MI, 20141, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
- New cocktail of drugs aims to keep HER2+ breast cancer in check
- New trial aims to beat cancer fatigue with common drug
- New shot could replace daily pill for advanced breast cancer
- Breast cancer drug IBRANCE® under Real-World watch in korea
- New drug combo shows promise in early breast cancer trial